Prostafexin®
Prostafexin® is a polyherbal formulation exhibiting combinatorial mechanism of action aimed at reducing prostate size. First, Prostafexin® specifically inhibits prostate 5α-reductase type 2.
NGN 150,000.00
Oncology
MyoFibrox®
NGN 180,000.00
MyoFibrox® is a polyherbal formulation exhibiting combinatorial mechanism of action aimed at reducing uterine size. First, MyoFibrox ® weakly inhibits nuclear receptor subfamily 3, group C, member 3 (progesterone receptor) and estrogen receptor (ER).
Additional Details
Since progesterone increases Bcl-2 protein expression in fibroid cells, which is a major factor driving their growth. Treatment with progesterone receptor modulators can reduce fibroid size by decreasing Bcl-2 levels and promoting apoptosis. MyoFibrox® is also a strong repressor of IGF-1/2 expression leading to blockage in uterine angiogenesis. TGF-β downstream signaling responsible for the abnormal growth and fibrotic nature of fibroids are blocked by MyoFibrox® treatment.
Quantity:
1
Related Products
Atxilox®
Atxilox® is a polyherbal formulation exhibiting varying mechanism of action. First, Atxilox® inhibits The Mammalian Target of Rapamycin (mTOR) kinase.
NGN 200,000.00
Metaxin®
Metaxin® modulates Epithelial-Mesenchymal Transition (EMT), whereas tumour cells loose adhesion to the primary tumor and extracellular matrix (ECM) promoted by proteolytic degradation of the ECM by enzymes like matrix metalloproteinases (MMPs); and the activation of signaling pathways that promote cell motility and survival. Broadly, Metaxin® has two mechanisms of action.
NGN 200,000.00